Deucravacitinib and Tapinarof: New Oral Options for Plaque Psoriasis Treatment

Executive Brief

News Report

The News: Deucravacitinib and tapinarof are newly approved treatments for plaque psoriasis.
Clinical Win: These therapies offer effective management options for patients with moderate to severe plaque psoriasis.
Target Specialty: Dermatology

Key Data at a Glance

Deucravacitinib dosing: 30 mg orally once daily
Tapinarof dosing: Applied once daily to affected areas

The recent introduction of oral deucravacitinib alongside topical tapinarof represents a significant advancement in the treatment landscape for plaque psoriasis. Approved in 2026, these therapies offer new options for patients who require effective management of this chronic condition.

Clinical Context

Plaque psoriasis is a chronic autoimmune skin disorder characterized by the rapid proliferation of skin cells, leading to thick, scaly patches on the skin. This condition affects approximately 2-3% of the global population and can significantly impair quality of life due to associated symptoms such as itching, discomfort, and psychological distress. Current treatments include topical agents, phototherapy, and systemic therapies, including biologics targeting IL-23, IL-17, and TNF pathways. Despite these options, many patients remain inadequately controlled, highlighting the need for new therapies that can provide effective and convenient treatment. The recent approval of deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, and tapinarof, a topical aryl hydrocarbon receptor modulating agent, offers promising alternatives for patients with moderate to severe plaque psoriasis, particularly those who may not respond to existing treatments.

Key Findings

The approval of deucravacitinib was based on its efficacy in reducing the severity of plaque psoriasis, demonstrating a significant improvement in the Psoriasis Area and Severity Index (PASI) scores compared to placebo in clinical trials [9].

Tapinarof has shown comparable efficacy, with studies indicating it effectively reduces plaque psoriasis lesions and improves patient-reported outcomes [6].

Both therapies can be used in combination, with early reports suggesting that the combination of oral deucravacitinib and topical tapinarof may enhance treatment outcomes in severe cases [9].

Dosing for deucravacitinib is typically 30 mg taken orally once daily, while tapinarof is applied to affected areas once daily, providing a convenient treatment regimen for patients [10].
Clinicians should consult current prescribing information for full dosing guidance.

What This Means for Clinical Practice

The introduction of deucravacitinib and tapinarof expands the therapeutic options available for managing plaque psoriasis, particularly for patients who have not responded to traditional therapies. Clinicians should consider these new agents for patients with moderate to severe plaque psoriasis, especially those seeking oral treatment alternatives or those who prefer topical applications. The combination therapy approach may also be beneficial for patients with more severe manifestations of the disease. As these treatments become integrated into practice, ongoing assessment of their long-term efficacy and safety profiles will be essential. How these new options will influence treatment guidelines and patient management strategies remains to be seen, but they represent a significant step forward in the management of plaque psoriasis.

Clinical Perspective

Workflow: The introduction of these therapies may streamline treatment decisions for dermatologists managing plaque psoriasis.

Economics: Cost considerations will be important as these new therapies are integrated into treatment protocols.

Patient Outcomes: Improved treatment options could lead to better patient adherence and satisfaction in managing plaque psoriasis.

Dr. Rohan Gupta, Dermatology

Deucravacitinib and Tapinarof: New Oral Options for Plaque Psoriasis Treatment

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

Atopic Dermatitis Biologics Comparison: Dupilumab, Tralokinumab, Lebrikizumab, and JAK Inhibitors

Dupilumab vs Tralokinumab vs Lebrikizumab vs Difamilast: Biologics Comparison for Atopic Dermatitis in 2025

FDA Approves Difamilast for Atopic Dermatitis: Expanding Options for Pediatric and Adult Patients

Verified HCP Portal